Elixirgen Therapeutics planning to begin Phase I/II Clinical Trials of its COVID-19 Vaccine Candidate EXG-5003 at Fujita Health University
BALTIMORE, Sept. 1, 2020 — Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery, development and commercialization of therapies for genetic diseases and vaccines, announced that Fujita Health University has received a contract from the Japan Agency for Medical Research and Development (AMED) to initiate Phase I/II clinical trials of the company’s COVID-19 […]